The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The Drug-Dosing Conundrum in Oncology — When Less Is More
Abstract
Doses and schedules of oncology drugs are sometimes inadequately characterized before registration trials. The “more is better” paradigm is still used for dose selection, despite the recognition that targeted therapies require alternative approaches to dose optimization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Nie, L., Rubin, E. H., Mehrotra, N., Pinheiro, J. C., Fernandes, L. L., Roy, A., Bailey, S., & de Alwis, D. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2644 · Cited by 68
Redefining the primary objective of phase I oncology trials
Ratain, M. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.135 · Cited by 59
Cited by
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398
FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC
Nakajima, E. C., Drezner, N., Li, X., Mishra-Kalyani, P. S., Liu, Y., Zhao, H., Bi, Y., Liu, J., Rahman, A., Wearne, E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3074 · Cited by 333
Self-citationExploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Metadata
- Authors
- Shah, M., Rahman, A., Theoret, M. R., & Pazdur, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-14
- Volume
- 385
- Issue
- 16
- Pages
- 1445-1447
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3204811815
- Cited by
- 295
- References
- 3
- FWCI
- 36.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Drug-Dosing Conundrum in Oncology — When Less Is More. https://app.cochat.ai/papers/10.1056/nejmp2109826
- The paper
- Shah, M., Rahman, A., Theoret, M. R., & Pazdur, R. (2021). The Drug-Dosing Conundrum in Oncology — When Less Is More. New England Journal of Medicine. https://doi.org/10.1056/nejmp2109826
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.